CD274 and cervical carcinoma: Indeed, preliminary results from the phase I DURVIT trial investigating intratumorally applied durvalumab (anti-PD-L1) in early cervical cancers [212] showed that this strategy is safe and more tolerable than systemically applied anti-PD-L1 therapy; none of the patients had adverse events exceeding grade 2 (Rotman et al.; manuscript in preparation).